HHS Says Nplate Order not Sign of Nuclear Threat
The US Department of Health and Human Services (HHS) said last week it has budgeted $290 million to stock up on Amgen’s Nplate (romiplostim), a drug primarily used to treat acute radiation sickness in the event of a nuclear emergency.
